UKUK

UK alliance on ninja antibodies

03.04.2012


London companies PolyThericsand Spirogen collaborate for betterantibody-drug-conjugates (ADCs) in theight against cancer.
The buzz around antibody-drug-conjugates (ADCs), the weapons of choice in the fight against cancer, just became more blatant. After last week’s news that a novel ADC company had been founded in Switzerland. PolyTherics Limited from London (UK) announced on 2 April that it would join in the treasure hunt for promising ADC candidates. Just like the Swiss ADC Therapeutics Sarl, London-seated PolyTherics relies on the cytotoxic agents provided by Spirogen Limited. The two companies want to combine PolyTherics’ linker technology „TheraPEGTM“ with Spirogen’s potent cytotoxic pyrrolobenzodiazepines („PBDs“). The aim is to connect PBDs via the new linker to antibodys or antibody fragments in a site-specific manner. PolyTherics CEO John Burt is enthusiastic: „This is an exciting opportunity to combine our validated conjugation technology with Spirogen’s potentially best-in-class PBD warheads.“ Also Spirogen CEO Chris Martin is convinced the collaboration will bear fruit: „ADCs will represent a significant medical breakthrough in cancer therapy. PolyTherics’ TheraPEGTM conjugation technology will broaden the applications where our PBD warheads and linkers can create highly potent potentially market-leading ADC candidates.“ Spirogen’s PBDs are DNA minor groove binding agents, which bind and cross-link specific DNA-sites. They block cell division in the targeted (cancer) cells without distorting their DNA helix, thus avoiding the common phenomenon of emergent drug resistance.

UKUK

14.11.2011

London – GlaxoSmithKline goes west. The British pharmaceutical company launched the $50-million GSK Canada Life Sciences Innovation Fund that will invest in “early-stage breakthrough research” in health care life science in...

UKUK

04.10.2011

Heidelberg/Cambridge/London– A team of researchers from GlaxoSmithKline, the biotech company Cellzome and from Universities Cambridge, Ulm and Amsterdam have found a promising treatment for mixed lineage (MLL-fusion) leukaemia...

UKUK

01.10.2011

Amersham – GE Healthcare intends to remain a major force in cancer therapy. Based in London, the health business of the US technology giant announced it will be reserving €730m of its total R&D budget over the next five years for...

UKUK

01.10.2011

Wolverhampton – One of the challenges for manufacturers of probiotic foods is getting large enough numbers of the bacteria into the intestines; most perish under the strongly acidic conditions in the stomach. Scientists from the...

UKUK

01.10.2011

Washington – British Shire plc gained more than 10% in late August on the London Stock Exchange after the US FDA approved Firazyr (icatibant) for acute attacks of hereditary angioedema. The compound was developed by Berlin-based...

UKUK

26.09.2011

London – The first clinical trial using human embryonic stem cells will be carried out at the Moorfields Eye hospital in London. Doctors will inject retinal cells into the eyes of 12 patients with Stargardt‘s macular dystrophy, a...

UKUK

20.09.2011

Amersham – GE Healthcare intends to stay a major force in cancer. The health business of the US-technological company, which is based in London, announced to reserve €730m of its total R&D budget over the next five years for...

UKUK

29.08.2011

Cambridge - A new biotech spin off from the University of Cambridge launched with €6.8m venture capital. Newco Mission Therapeutics Ltd. plans to develop cancer drugs targeting enzymes in ubiquitin pathways that control cellular...

UKUK

23.08.2011

London - GlaxoSmithKline has invested about €1.5m to take a 25.4 percent stake in Autifony Therapeutics, a British biotechnology company spun out of GSK to research treatments for tinnitus and hearing loss. Autifony’s other...

Displaying results 21 to 30 out of 396

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-uk/browse/2/article/uk-alliance-on-ninja-antibodies.html

Events

All Events

Stock list

All quotes

TOP

  • CO.DON2.84 EUR4.80%
  • VITA 343.98 EUR4.19%
  • MEDIGENE4.07 EUR2.26%

FLOP

  • THERAMETRICS0.08 CHF-11.11%
  • CYTOS0.24 CHF-4.00%
  • BASILEA97.25 CHF-1.22%

TOP

  • SANTHERA93.80 CHF46.3%
  • CO.DON2.84 EUR19.3%
  • FORMYCON8.22 EUR18.8%

FLOP

  • EVOTEC3.09 EUR-17.6%
  • MEDIGENE4.07 EUR-13.8%
  • 4SC1.16 EUR-12.8%

TOP

  • SANTHERA93.80 CHF2036.7%
  • CO.DON2.84 EUR226.4%
  • PAION2.69 EUR158.7%

FLOP

  • CYTOS0.24 CHF-94.0%
  • THERAMETRICS0.08 CHF-46.7%
  • MERCK KGAA67.56 EUR-41.3%

No liability assumed, Date: 15.09.2014


Current issue

All issues

Product of the week

Products